| Hepatitis C, Chronic
Alvaiz vs Harvoni
Side-by-side clinical, coverage, and cost comparison for hepatitis c, chronic.Deep comparison between: Alvaiz vs Harvoni with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsHarvoni has a higher rate of injection site reactions vs Alvaiz based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Harvoni but not Alvaiz, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Alvaiz
Harvoni
At A Glance
Oral
Daily
TPO-receptor agonist
Oral
Once daily
NS5A inhibitor + NS5B polymerase inhibitor
Indications
- Immune thrombocytopenic purpura
- Hepatitis C, Chronic
- Severe Aplastic Anemia
- Hepatitis C, Chronic
Dosing
Immune thrombocytopenic purpura Initiate at 36 mg orally once daily (18 mg for East-/Southeast-Asian ancestry or hepatic impairment; 9 mg for both); adjust in 18-mg increments to maintain platelet count >=50 x 10^9/L; maximum 54 mg daily.
Hepatitis C, Chronic Initiate at 18 mg orally once daily; adjust in 18-mg increments every 2 weeks to achieve platelet count needed to initiate or maintain pegylated interferon and ribavirin therapy; maximum 72 mg daily; discontinue when antiviral therapy is discontinued.
Severe Aplastic Anemia Initiate at 36 mg orally once daily (18 mg for East-/Southeast-Asian ancestry or hepatic impairment); adjust in 36-mg increments every 2 weeks to maintain platelet count >=50 x 10^9/L; maximum 108 mg daily.
Hepatitis C, Chronic (Genotype 1, treatment-naive or treatment-experienced without cirrhosis or with compensated cirrhosis) 90 mg ledipasvir/400 mg sofosbuvir orally once daily for 12 weeks (8 weeks may be considered in treatment-naive patients without cirrhosis with HCV RNA <6 million IU/mL); 24 weeks in treatment-experienced with compensated cirrhosis
Hepatitis C, Chronic (Genotype 1, with decompensated cirrhosis) 90 mg ledipasvir/400 mg sofosbuvir orally once daily + ribavirin for 12 weeks
Hepatitis C, Chronic (Genotype 1 or 4, liver transplant recipients) 90 mg ledipasvir/400 mg sofosbuvir orally once daily + ribavirin for 12 weeks
Hepatitis C, Chronic (Genotype 4, 5, or 6, without cirrhosis or with compensated cirrhosis) 90 mg ledipasvir/400 mg sofosbuvir orally once daily for 12 weeks
Contraindications
—
- When administered with ribavirin, all contraindications to ribavirin apply to the combination regimen
Adverse Reactions
Most common (>=3%) Nausea, diarrhea, upper respiratory tract infection, vomiting, urinary tract infection, increased ALT, myalgia, oropharyngeal pain, increased AST, pharyngitis, back pain, influenza, paresthesia, rash
Serious Hemorrhage, thrombotic/thromboembolic complications, hepatic decompensation, hepatotoxicity, cataracts
Postmarketing Skin discoloration including hyperpigmentation and skin yellowing
Most common (>=10%) Fatigue, headache
Serious Serious symptomatic bradycardia when coadministered with amiodarone
Postmarketing Skin rashes, sometimes with blisters or angioedema-like swelling, angioedema
Pharmacology
Eltrombopag is a TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor (cMpl), initiating signaling cascades that induce proliferation and differentiation of megakaryocytes, leading to increased platelet production.
Ledipasvir inhibits the HCV NS5A protein required for viral replication, and sofosbuvir inhibits the HCV NS5B RNA-dependent RNA polymerase, which is also required for viral replication.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Alvaiz
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (1/12)
Harvoni
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Alvaiz
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (0/8)
Harvoni
- Covered on 4 commercial plans
- PA (7/8) · Step Therapy (4/8) · Qty limit (7/8)
Humana
Alvaiz
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Harvoni
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availablePAF Co-Pay Relief: Aplastic Anemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Harvoni.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AlvaizView full Alvaiz profile
HarvoniView full Harvoni profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.